MedPath

Tilmanocept

Generic Name
Tilmanocept
Brand Names
Lymphoseek
Drug Type
Small Molecule
CAS Number
1185986-76-8
Unique Ingredient Identifier
MDU8BQ474H
Background

Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).

Associated Conditions
Breast Cancer, Melanoma, Oral Cancer
Clinical Trials
Related News

Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

Phase 4
Conditions
Sentinel Lymph Node Biopsy
Breast Cancer
Interventions
Drug: Tc 99m filtered sulfur colloid
First Posted Date
2017-06-27
Last Posted Date
2018-08-24
Lead Sponsor
Memorial Health University Medical Center
Target Recruit Count
86
Registration Number
NCT03199560
Locations
🇺🇸

Memorial Health University Medical Center, Savannah, Georgia, United States

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

Phase 1
Terminated
Conditions
Liver Metastases
Colorectal Carcinoma
Interventions
Procedure: SPECT/CT Imaging
First Posted Date
2017-01-24
Last Posted Date
2020-09-10
Lead Sponsor
Navidea Biopharmaceuticals
Target Recruit Count
3
Registration Number
NCT03029988
Locations
🇺🇸

University of Alabama Birmingham, Birmingham, Alabama, United States

A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus

Phase 2
Withdrawn
Conditions
Anal Cancer
Interventions
First Posted Date
2016-08-05
Last Posted Date
2017-03-15
Lead Sponsor
Cardinal Health 414, LLC
Registration Number
NCT02857608

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2016-02-17
Last Posted Date
2019-11-21
Lead Sponsor
Navidea Biopharmaceuticals
Target Recruit Count
18
Registration Number
NCT02683421
Locations
🇺🇸

Axis Clinical Trials, Los Angeles, California, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium

Phase 1
Terminated
Conditions
Endometrial Cancer
Interventions
First Posted Date
2015-10-28
Last Posted Date
2018-10-15
Lead Sponsor
University of California, San Diego
Target Recruit Count
2
Registration Number
NCT02589366
Locations
🇺🇸

University of California, San Diego Moores Cancer Center, La Jolla, California, United States

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Phase 2
Completed
Conditions
Rhabdomyosarcoma
Melanoma
Interventions
Drug: Vital Blue Dye (optional)
Procedure: Lymph Node Mapping
First Posted Date
2015-07-28
Last Posted Date
2024-06-28
Lead Sponsor
Cardinal Health 414, LLC
Target Recruit Count
24
Registration Number
NCT02509598
Locations
🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Nemours Children's Specialty Care, Jacksonville, Florida, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

and more 3 locations

A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Phase 2
Terminated
Conditions
Uterine Cervical Neoplasms
Interventions
First Posted Date
2015-07-28
Last Posted Date
2019-02-11
Lead Sponsor
Cardinal Health 414, LLC
Target Recruit Count
18
Registration Number
NCT02509585
Locations
🇺🇸

University of California, San Diego, La Jolla, California, United States

🇺🇸

Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

and more 1 locations

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

Phase 4
Completed
Conditions
Breast Cancer
Interventions
Drug: Sulfur Colloid
First Posted Date
2014-11-11
Last Posted Date
2020-07-28
Lead Sponsor
Kettering Health Network
Target Recruit Count
40
Registration Number
NCT02287675
Locations
🇺🇸

Kettering Medical Center, Kettering, Ohio, United States

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

Phase 2
Completed
Conditions
Kaposi's Sarcoma
Interventions
First Posted Date
2014-07-28
Last Posted Date
2016-09-27
Lead Sponsor
Navidea Biopharmaceuticals
Target Recruit Count
5
Registration Number
NCT02201420
Locations
🇺🇸

San Francisco General Hospital, San Francisco, California, United States

Sentinel Lymph Node Mapping Post-Injection Site Pain

Completed
Conditions
Breast Cancer
Interventions
Drug: Sulfur Colloid
First Posted Date
2014-02-17
Last Posted Date
2019-08-14
Lead Sponsor
University of California, San Diego
Target Recruit Count
52
Registration Number
NCT02065232
Locations
🇺🇸

University of California, San Diego, San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy